Abstract 573P
Background
Tumour infiltrating CD8+ cytotoxic T cells confer favourable prognosis in colorectal cancer (CRC). The added prognostic value of other immune cells is unclear.
Methods
We used multiparameter co-immunofluorescence to determine the density of CD8+, CD20+, FoxP3+ and CD68+ cells in the intraepithelial (IE) and intrastromal (IS) compartments in stage II/III CRCs from the SCOT and QUASAR2 trials. We determined marker prognostic and predictive value by Cox regression of SCOT cases, with validation in the QUASAR2 cohort.
Results
Our study included 2,340 SCOT and 1,069 QUASAR2 cases. Univariable analysis of recurrence-free interval (RFI) in SCOT revealed expected prognostic value of intraepithelial CD8 (CD8IE) (continuous variable: HR for cases at 75th vs 25th percentile (HR75vs25)= 0.73, 95% CI=0.68-0.79, P=2.5e-16) and, less expectedly FoxP3 within tumour stroma (FoxP3IS) (HR75vs25)= 0.71, 95% CI=0.64-0.78, P=1.5e-13), but not epithelium. CD8IE and FoxP3IS were independently prognostic in multivariable analysis, and a composite marker including both (CD8IE-Foxp3IS) was superior to either alone as a continuous variable (adjHR75vs25= 0.70; 95%CI=0.63–0.78; P=5.1e-11), and when categorised into three groups (Low/Int/High) using sample medians (Int vs High HR = 1.60, 95%CI=1.24–2.05, P=2.5e-04; Low vs High HR = 2.30, 95%CI=1.80–2.95; P=3.6e-11). These results were validated in the QUASAR2 trial. Pooled analysis of both studies revealed interactions between CD8IE-FoxP3IS and tumour sidedness (adjP INT=0.010), stromal proportion (adjP INT=0.018), and MMR status (adjP INT=0.079). CD8IE-FoxP3IS refined stage III risk groups, with clinical low risk (T1-3, N1), CD8IE-FoxP3IS low cases demonstrating similar 3-year recurrence-free probability to clinical high risk (T4 and/or N2), CD8IE-FoxP3IS high cases (79.2 vs 76.4%, adj log-rank P=0.16).
Conclusions
Combined evaluation of CD8IE and FoxP3IS is superior to single markers and refines CRC risk stratification. FoxP3IS prognostic value is inconsistent with an immunosuppressive role; further investigation of these cells as an immunotherapy target is merited.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
D.N. Church.
Funding
Cancer Research UK, National Institutes for Health Research, Promedica Foundation.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
622P - Evaluation of the metastatic colorectal cancer score (mCCS) in predicting outcome for patients with RAS wild type metastatic colorectal cancer (mCRC) treated with first-line (1L) panitumumab (PAN) plus FOLFIRI/FOLFOX: Updated interim results of the non-interventional study VALIDATE
Presenter: Marcel Reiser
Session: Poster session 10
623P - VIC regimen (vemurafenib/irinotecan/cetuximab) versus bevacizumab plus chemotherapy as first-line treatment for BRAF V600E-mutated advanced colorectal cancer
Presenter: Yijiao Chen
Session: Poster session 10
624P - Tolerability and safety of vemurafenib, cetuximab combined with camrelizumab for BRAF V600E-mutated /MSS metastatic colorectal cancer
Presenter: Meng Qiu
Session: Poster session 10
625P - Efficacy and safety of the combination of encorafenib and cetuximab in patients with BRAF V600E mutated metastatic colorectal cancer: An AGEO real-world multicentre study
Presenter: Claire Gallois
Session: Poster session 10
626P - Mucinous differentiation (MD) as predictor of response in BRAF-V600E mutated metastatic colorectal cancer (mCRC) treated with BRAF inhibitors (BRAFi) combinations
Presenter: Francisco Javier Ros Montana
Session: Poster session 10